Search

Biopsies from 55 female patients with benign breast disease (BBD) were assayed for estrogen receptor. Scatchard analyses were utilized to quantify the number of binding sites. Computer-assisted methods analyzed the data. A + estrogen receptor assay is equal or greater than 10 femtomoles of (3H) estradiol binding per mg of cytoplasmic protein. Statistical methods used for analysis included contingency chi-square test and Wilcoxon Rank-Sum test. 38% (21) of the patients had + estrogen receptor assay. 55% of the fibroadenomas were + for estrogen receptor compared to 17% for other benign lesions (4 patients with fibrocystic disease). No correlation was found between estrogen receptor positivity and laterality of tumor and location or size of largest nodule. The mean age of patients with estrogen receptor + tumors was 26.9 years compared with 36.4 years for patients with estrogen receptor - tumors (p < 0.01). 20 of 46 (43%) premenopausal patients were found to have estrogen receptor + tumors in contrast to 0 of 8 postmenopausal patients (p < 0.05). A decreased incidence of BBD has been associated with oral contraceptive (OC) use. The pharmacologic doses of estrogen in OCs may play a role in controlling the growth of BBD or in the regressions of some metastatic breast cancer deposits; this concept raises the possible role of antiestrogens (e.g. Tamoxifen) in the treatment of BBD.

The amino esters (I), mostly prepared from the corresponding acyl chlorides or acids, are studied for antispasmodic activity.